Education
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
NASDAQ:CSTL
CSTL Stock Chart & Stats
$40.01
-$0.86(-2.67%)
At close: 4:00 PM EST
$40.01
-$0.86(-2.67%)
Day’s Range― - ―
52-Week Range$14.59 - $42.18
Previous CloseN/A
Volume108.23K
Average Volume (3M)339.96K
Market Cap
$1.17B
Enterprise Value$1.12B
Total Cash (Recent Filing)$287.54M
Total Debt (Recent Filing)$37.14M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Mar 04, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding29,188,660
10 Day Avg. Volume374,957
30 Day Avg. Volume339,964
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)1.62
Price to Sales (P/S)2.23
P/FCF Ratio20.26
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue3.26
Enterprise Value/Gross Profit4.08
Enterprise Value/Ebitda43.40
Forecast
1Y Price Target
$47.20Price Target Upside17.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.19
Revenue Forecast (FY)$337.09M
Bulls Say, Bears Say
Bulls Say
Guidance And Test VolumesAnalyst's note indicates the company raised annual revenue guidance after stronger-than-expected test volumes, with the melanoma test outperforming and supporting upside to sales forecasts.
New Product Commercial LaunchCommercial launch of AdvanceAD-Tx targets the atopic dermatitis treatment market and could create a sizable new revenue stream if clinician uptake is solid.
TissueCypher Adoption And MarginsRapid commercial adoption of the TissueCypher test is driving substantial revenue growth while the business sustains industry-leading gross margins, strengthening profitability prospects.
Bears Say
Medicare Coverage LossRemoval of Medicare coverage for the SCC skin-cancer test and the discontinuation of another test reduced revenue and created a material headwind to top-line momentum.
Reimbursement UncertaintyPending reconsideration of Medicare coverage leaves reimbursement outcomes uncertain and poses downside risk to revenue if decisions are unfavorable.
Revenue Concentration RiskHeavy reliance on rapid TissueCypher growth to offset lost reimbursement concentrates revenue risk and could increase earnings volatility if adoption slows.
Castle Biosciences News
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $14.59 and its highest was $42.17 in the past 12 months.
What is Castle Biosciences’s market cap?
Castle Biosciences’s market cap is $1.17B.
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is Mar 04, 2026 which is in 44 days.
How were Castle Biosciences’s earnings last quarter?
Castle Biosciences released its earnings results on Nov 03, 2025. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.521 by $0.501.
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Undervalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate is -0.32.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 29,188,660 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Castle Biosciences reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.521. Following the earnings report the stock price went up 21.701%.
Which hedge fund is a major shareholder of Castle Biosciences?
Currently, no hedge funds are holding shares in CSTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Castle Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.20 (17.97% Upside)
$47.20 (17.97% Upside)
Blogger Sentiment
Bullish
CSTL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 20.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.46%
12-Months-Change
Fundamentals
Return on Equity
-2.69%
Trailing 12-Months
Asset Growth
9.37%
Trailing 12-Months
Company Description
Castle Biosciences
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
CSTL Company Deck
CSTL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Castle Biosciences demonstrated strong revenue growth, launched a new dermatological test, and achieved record test report volumes. However, challenges include a decline in gross margin, reporting a net loss, and uncertainties in SCC reimbursement. Despite these challenges, the company's positive momentum and strategic initiatives suggest a well-balanced performance.View all CSTL earnings summariesCSTL Stock 12 Month Forecast
Average Price Target
$47.20
▲(17.97% Upside)
Technical Analysis
Ownership Overview
2.37% Insiders
23.84% Mutual Funds
0.13% Other Institutional Investors
59.64% Public Companies and
Individual Investors